

**SODIUM CHLORIDE- sodium chloride solution**  
**Baxter Healthcare Corporation**

-----  
**0.9% Sodium Chloride Processing Solution**  
**in Flexible Plastic Container**  
**Not for injection**

**DESCRIPTION**

Sodium Chloride Processing Solution is a sterile, nonpyrogenic solution in single dose container for use in blood cell processing devices. It contains no antimicrobial agents. Composition, osmolarity, pH, and ionic concentration are shown in Table 1.

**Table 1**

0.9% Sodium Chloride Processing Solution	Size (mL)	Composition (g/L)	Osmolarity (mOsmol/L) (calc)	pH	Ionic Concentration (mEq/L)	
		Sodium Chloride, USP (NaCl)			Sodium	Chloride
	3000	9	308	5.5 (4.5 to 7.0)	154	154

The plastic container is fabricated from a specially formulated polyvinyl chloride (**PL 146** Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexylphthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

**CLINICAL PHARMACOLOGY**

0.9% Sodium Chloride Processing Solution has value as a physiological blood cell processing aid.

**INDICATIONS AND USAGE**

0.9% Sodium Chloride Processing Solution is indicated in processing blood cells.

See directions accompanying blood cell processing device for complete instructions for use.

**CONTRAINDICATIONS**

None known

## **WARNINGS**

This container should not be connected for direct intravenous administration.

The contents of an opened container should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. Discard the unused portion of processing solution.

## **PRECAUTIONS**

Careful review and understanding of the use of this solution in conjunction with blood cell processing equipment is essential.

### **Pregnancy**

Teratogenic Effects

*Pregnancy Category C.*

Animal reproduction studies have not been conducted with 0.9% Sodium Chloride Processing Solution. It is also not known whether 0.9% Sodium Chloride Processing Solution can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 0.9% Sodium Chloride Processing Solution should be given to a pregnant woman only if clearly needed.

### **Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

Do not administer unless solution is clear and seal is intact.

## **ADVERSE REACTIONS**

None known

## **DOSAGE AND ADMINISTRATION**

As directed by a physician. See directions accompanying blood cell processing device.

Processing Solutions should be inspected visually for particulate matter and discoloration prior to use.

## **HOW SUPPLIED**

0.9% Sodium Chloride Processing Solution in Flexible Plastic Container is available as follows:

<b>Code</b>	<b>Size (mL)</b>	<b>NDC</b>
2B7207	3000	0338-0050-47

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25° C); brief exposure up to 40° C does not adversely affect the product.

### **To Open**

Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

### **Preparation for Use**

1. Suspend container from eyelet support.
2. Remove plastic protector from outlet port at bottom of container.
3. Attach to blood cell processing device. Refer to complete directions accompanying blood cell processing device.

### **Baxter Healthcare Corporation**

Deerfield, IL 60015 USA

Printed in USA

©Copyright 1983, 1990, 1995, Baxter Healthcare Corporation. All rights reserved.

07-19-73-065

Rev. May 2014

BAXTER, AND PL 146 ARE TRADEMARKS OF BAXTER INTERNATIONAL INC.

### **PACKAGE/LABEL PRINCIPAL DISPLAY PANEL**



3000 mL

2B7207

NDC 0338-0050-47

NOT FOR INJECTION

0.9%

SODIUM CHLORIDE

Processing Solution

EACH 100 mL CONTAINS 900 mg SODIUM CHLORIDE USP  
 NO ANTIMICROBIAL AGENT HAS BEEN ADDED pH 5.5 (4.5 TO 7.0)  
 mEq/L SODIUM 154 CHLORIDE 154 OSMOLARITY 308  
 mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE  
 CONTAINER

DOSAGE AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS  
 ACCOMPANYING BLOOD CELL PROCESSING DEVICE FOR USE THIS  
 CONTAINER SHOULD NOT BE CONNECTED FOR DIRECT INTRAVENOUS  
 ADMINISTRATION

CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS  
PRODUCT STERILITY DISCARD IF LEAKS ARE FOUND DO NOT USE  
UNLESS SOLUTION IS CLEAR DISCARD UNUSED PORTION **RX ONLY**  
STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE  
(25°C) UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT

0.9%

Sodium Chloride

NaCl

Processing Solution

VIAFLEX CONTAINER

PL146 PLASTIC

## FOR PRODUCT INFORMATION

1-800-933-0303

### ***Baxter Logo***

Baxter Healthcare Corporation  
Deerfield, IL 60015 USA

Made in USA

Baxter VIAFLEX and  
PL 146 are trademarks of  
Baxter International Inc

## SODIUM CHLORIDE

sodium chloride solution

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0338-0050
Route of Administration	EXTRACORPOREAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698)	SODIUM CHLORIDE	900 mg in 100 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>WATER</b> (UNII: 059QF0KO0R)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
---	-----------	---------------------	----------------------	--------------------

<b>1</b>	NDC:0338-0050-47	4 in 1 CARTON	05/30/1980	
<b>1</b>		3000 mL in 1 BAG; Type 0: Not a Combination Product		
<b>Marketing Information</b>				
<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>		<b>Marketing Start Date</b>	<b>Marketing End Date</b>
NDA	NDA017867		05/30/1980	

**Labeler** - Baxter Healthcare Corporation (005083209)

<b>Establishment</b>			
<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Baxter Healthcare Corporation		059140764	MANUFACTURE(0338-0050) , STERILIZE(0338-0050) , PACK(0338-0050) , LABEL(0338-0050) , ANALYSIS(0338-0050)

<b>Establishment</b>			
<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Baxter Healthcare Corporation		194684502	ANALYSIS(0338-0050)

Revised: 7/2014

Baxter Healthcare Corporation